Effectiveness of the biofungicide AXPERA against grapevine downy mildew

Amoéba, a specialist in microbiological solutions, has announced the success of trials of its biocontrol product, AXPERA, against grapevine mildew. Conducted in collaboration with IFV+, the study was conducted in the South-West of France. These trials show that AXPERA, combined with a reduced dose of copper, reduces mildew symptoms by 57.7% compared to an untreated control.

In difficult conditions, with excess rainfall, the biofungicide outperformed conventional copper-based treatments, which only reduced symptoms by 37.5%. AXPERA could therefore be a sustainable alternative to traditional phytosanitary products. Amoéba expects the product to be approved in France by the end of 2025/beginning of 2026.